Q1 2024 Jaguar Health Inc Earnings Call Transcript
Key Points
- Jaguar Health Inc reported a 20% increase in Q1 2024 net revenue compared to Q1 2023, and a 4% increase compared to Q4 2023.
- The company has expanded its commercial footprint into cancer-related supportive care with the in-licensing of FDA-approved oral mucositis product Gelclair.
- Jaguar Health Inc is actively pursuing new opportunities in oncology supportive care, aiming to establish a leadership role in this area.
- The company has multiple clinical efforts across the globe, including trials for rare diseases with potential for early patient access programs in Europe.
- Net loss attributable to common shareholders decreased by approximately $2.9 million from Q1 2023 to Q1 2024.
- Mytesi prescription volume decreased by 7% in Q1 2024 compared to Q4 2023 due to insurance deductibles reset.
- Prescriptions of Mytesi slightly decreased by 2.5% in Q1 2024 compared to Q1 2023.
- Despite improvements, the company still reported a substantial loss from operations of $8.2 million in Q1 2024.
- Non-GAAP recurring EBITDA reported a net loss of $7.5 million in Q1 2024.
- The company faces uncertainties regarding market acceptance of new products and competitive pressures.
Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the Company. uncertainties regarding market acceptance of products. The impact of competitive products and pricing, industry trends and product initiatives, including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These statements are based on currently available information and management's current assumptions, expectations and projections about future events.
While management believes its assumptions, expectations and projections are reasonable in view of currently available information, you are cautioned not to place undue reliance on these forward-looking statements.
The company's actual results may differ materially from those discussed during the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
